Compare Prologis Inc (PLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Prologis Inc trades at $129.52 (market cap $120.98B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Prologis Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Prologis Inc pays a 3.36% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PLD | VRTX | |
|---|---|---|
Market Cap | $120.98B | $128.16B |
Volume | 3,604,776 | 806,603 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $557.96 |
52-Week Low | $111.23 | $407.37 |
Typical Hold Time | 102 Days | 120 Days |
Enterprise Value | $155.72B | $122.29B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $129.29, up 0.47% today, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Revenue grew to $8.79B in 2025, and net income margin stands strong at 45.79%. Recent news highlights strong leasing activity and data center growth potential, though the stock faces near-term resistance near $129.
The outlook for PLD is positive, supported by robust fundamentals and analyst consensus favoring a buy rating with a $155.15 price target. Key opportunities include e-commerce and data center demand driving rent growth. Risks involve rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and broader REIT sector volatility amid interest rate concerns.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
